(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 September 2019 (06.09.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/166631 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 31/353* (2006.01)
A61K 47/24 (2006.01)

(21) International Application Number:
PCT/EP2019/055149

(22) International Filing Date:
01 March 2019 (01.03.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18159727.9 02 March 2018 (02.03.2018) EP
62/637,676 02 March 2018 (02.03.2018) US

(71) Applicant: **NOVALIQ GMBH** [DE/DE]; Im Neuenheimer Feld 515, 69120 Heidelberg (DE).

(72) Inventors: **LÖSCHER, Frank**; Burgweg 31, 69198 Schriesheim (DE). **EICKHOFF, Kirsten**; Planckstr. 25, 63741 Aschaffenburg (DE). **STREHL, Diana**; Schillerstrasse 30, 69115 Heidelberg (DE).

(74) Agent: **PHARMA PATENTS INTERNATIONAL AG**; Leonhardsgraben 52, 4051 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL




Figure 1

(57) **Abstract:** The present invention relates to pharmaceutical compositions comprising the selective beta 1(β1) - receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

[Continued on next page]

WO 2019/166631 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*